Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic therapeutics for people with life-threatening conditions. Its pipeline includes two key candidates: INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5, currently in phase 1 trials for unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX40, being evaluated for multiple solid tumors including non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. The company operates in the biotechnology industry within the healthcare sector.

Inhibrx Biosciences, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol INBX. The trading currency is the US Dollar (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, it is subject to the exchange's listing requirements and reporting standards, providing investors with liquidity and transparency.

Inhibrx Biosciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing biologic therapeutics, which are drugs derived from living organisms. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight. Inhibrx's work in targeting death-receptor 5 and OX40 places it in the oncology and immunotherapy subfields of biotechnology.

Inhibrx Biosciences, Inc. is headquartered in La Jolla, California, United States. The company's geographic focus is primarily the US market, as indicated by its US region classification. La Jolla is a notable hub for biotechnology and life sciences research, providing access to talent and collaboration opportunities. While the company's clinical trials may involve sites in multiple countries, its operations and corporate activities are centered in the United States.